Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Strides Shasun Ltd    STAR   INE939A01011

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Strides Arcolab Limited : Strides Arcolab Receives US FDA Nod To Commercialize First Liquid Injectable Product From Its New Facility

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2012 | 03:03am CEST

Press Release
Wednesday, April 13, 2011

Strides Arcolab Limited, Strides House, Bannerghatta Road, Bangalore - 560076, India

BSE: 532531

NSE: STAR

STRIDES ARCOLAB RECEIVES US FDA NOD TO COMMERCIALIZE

FIRST LIQUID INJECTABLE PRODUCT FROM ITS NEW FACILITY

• First shipments to commence in April 2011

April 13, 2011, Bangalore: Strides Arcolab Limited (Strides) today announced that it has received approval from the US FDA to commercialize the first liquid injection sterile product from the Company's new Sterile Injectable complex in Bangalore. The approved product has been facing prolonged shortage in the USA and approval from the new facility will offer Strides unconstrained capacities to meet the market demand.

With this approval, significant capacity will be released from the existing site enabling

Strides to commercialize additional liquid injectable products.

Strides had earlier announced approval for Vancomycin Injection from its new facility in Bangalore in a lyophilized format and the Company has already started supplies to the US market in March 2011.

Commenting on this development Venkat Iyer, CEO, Agila Specialties, said, "The US FDA approval for the product from the new site will go a long way in ameliorating product shortages in critical therapeutic areas. Two significant product approvals from the new facility augur well for the launch of a series of products in the USA during 2011"

For reasons of confidentiality, the Company is not in a position to disclose the name of the product.

About Agila Specialties

Agila Specialties Private Limited is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 7 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.
The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350- scientist strong global R&D Centre located in Bangalore.
Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

Strides

PR Consultancy

Mr. V.S. Iyer, CEO - Agila
+91 80 66580111
Mr. Kannan. N (Investors)
+91 98450 54745
Melissa Arulappan (Media)
+91 98450 22389
Corporate Voice | Weber Shandwick
Mahesh Nair,
+91 9880376648 [email protected]
Hiba Kunil
+91 98807 26372 [email protected]

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on STRIDES SHASUN LTD
10/10 STRIDES SHASUN : stock rallies 4% after block deal
09/21 STRIDES SHASUN : Lipid drug gets usfda nod
09/20 STRIDES SHASUN : receives USFDA approval for Omega-3-Acid Ethyl Esters capsules
09/13 STRIDES SHASUN : gets USFDA nod for kidney stone tablets
09/09 STRIDES SHASUN : Oncobiologics announces strategic partnership with GMS Tenshi H..
09/07 STRIDES ARCOLAB LIMITED : ex-dividend day for annual dividend
09/02 STRIDES SHASUN : Gets inspection report from usfda
09/01 STRIDES SHASUN : Arrow Pharma acquires Australian operations of Amneal Pharma
09/01 STRIDES SHASUN : Bangalore facility gets EIR from USFDA
09/01 STRIDES SHASUN : Arm buys australian operations of amneal pharma
More news
Financials ( INR)
Sales 2018 37 820 M
EBIT 2018 5 016 M
Net income 2018 3 573 M
Debt 2018 20 855 M
Yield 2018 0,73%
P/E ratio 2018 22,43
P/E ratio 2019 14,58
EV / Sales 2018 2,64x
EV / Sales 2019 2,21x
Capitalization 78 861 M
Chart STRIDES SHASUN LTD
Duration : Period :
Strides Shasun Ltd Technical Analysis Chart | STAR | INE939A01011 | 4-Traders
Technical analysis trends STRIDES SHASUN LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 1 105  INR
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Shashank Sinha Chief Executive Officer, Director & MD
Arun N. Kumar Non-Executive Chairman
Ramaraju P. V. S Chief Operations Officer
Badree Komandur Chief Financial Officer & Director
Sunil Nadkarni Chief Technical Services Officer
Sector and Competitors